Literature DB >> 20159801

Bevacizumab and recurrent malignant gliomas: a European perspective.

Wolfgang Wick, Michael Weller, Martin van den Bent, Roger Stupp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20159801     DOI： 10.1200/JCO.2009.26.9027

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  37 in total

Review 1.  Antiangiogenic therapy for glioblastoma: current status and future prospects.

Authors:  Tracy T Batchelor; David A Reardon; John F de Groot; Wolfgang Wick; Michael Weller
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

Review 2.  Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.

Authors:  Wolfgang Wick; Antje Wick; Markus Weiler; Michael Weller
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

Review 3.  [Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].

Authors:  G Tabatabai; R Stupp
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

4.  Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

Authors:  David A Reardon; Annick Desjardins; Katherine B Peters; Sridharan Gururangan; John H Sampson; Roger E McLendon; James E Herndon; Anuradha Bulusu; Stevie Threatt; Allan H Friedman; James J Vredenburgh; Henry S Friedman
Journal:  J Neurooncol       Date:  2011-10-11       Impact factor: 4.130

Review 5.  Surgical management of high-grade glioma: a standard of care.

Authors:  Colin Watts
Journal:  CNS Oncol       Date:  2012-11

6.  Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.

Authors:  Roger Stupp; Michael Weller
Journal:  Neuro Oncol       Date:  2014-06       Impact factor: 12.300

Review 7.  On glioblastoma and the search for a cure: where do we stand?

Authors:  John Bianco; Chiara Bastiancich; Aleksander Jankovski; Anne des Rieux; Véronique Préat; Fabienne Danhier
Journal:  Cell Mol Life Sci       Date:  2017-02-17       Impact factor: 9.261

8.  Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab.

Authors:  Marc C Chamberlain; Sandra K Johnston
Journal:  J Neurooncol       Date:  2010-08-01       Impact factor: 4.130

9.  Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma.

Authors:  Rong Shao; Ralph Francescone; Nipaporn Ngernyuang; Brooke Bentley; Sherry L Taylor; Luis Moral; Wei Yan
Journal:  Carcinogenesis       Date:  2013-11-26       Impact factor: 4.944

10.  EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.

Authors:  Enrico Franceschi; Roger Stupp; Martin J van den Bent; Carla van Herpen; Florence Laigle Donadey; Thierry Gorlia; Monika Hegi; Benoit Lhermitte; Lewis C Strauss; Anouk Allgeier; Denis Lacombe; Alba A Brandes
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.